Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P110019/S145

XIENCE PRO5 Everolimus Eluting Coronary Stent System (XIENCE PRO5), XIENCE Skypoint Everolimus Eluting Coronary Stent Sy

Abbott Vascular · Decision date Oct 1, 2026

FDA DECISIONP110019/S145

What did the FDA decide?

FDA records P110019/S145 as a supplement to PMA P110019, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 1, 2026.

FDA approval order statement

an automated packaging process
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 1, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P110019/S145
Regulatory pathway
PMA supplement
Product code
NIQ
Decision code
OK30
Decision date
Oct 1, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Coronary drug-eluting stent.

Product code
NIQ
FDA device class
3

For the original device and its historical approval scope, see PMA P110019. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P110019 · Original PMA

    Xience Skypoint Everolimus Eluting Coronary Stent System

  2. P110019/S145 received

    Application receipt date recorded by FDA.

  3. P110019/S145 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P110019. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P110019

Product / regulatory recordCompanyPathwayDecision dateSource
Abbott VascularPMA approvalNov 1, 2011FDA

Explore the linked device profile

Other records with product code NIQ

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic VascularPMA supplementOct 16, 2026FDA
Biotronik AGPMA supplementSep 24, 2026FDA
Biotronik AGPMA approvalFeb 22, 2019FDA
Medtronic VascularPMA approvalApr 28, 2017FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Vascular

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3200 Lakeside Dr., Santa Clara, CA, 95054

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records